FDA Brief

Warning letters Drugs

FDA warning letter to

Devalingam Mahalingam, M.D., Ph.D.

High riskIssued Dec 11, 2025Posted Dec 30, 2025Center for Drug Evaluation and Research (CDER)

FDA warns clinical investigator Devalingam Mahalingam, M.D., Ph.D. over a 100-fold investigational drug overdose that led to a subject's death.

What happened

FDA inspected the clinical site from October 7 to October 18, 2024, as part of its Bioresearch Monitoring Program. FDA found that the investigator did not follow the investigational plan when a subject received about 1060 mcg of an investigational drug instead of the intended 10.674 mcg, about 100 times the protocol-required dose, after dilution procedures were not followed. The subject was hospitalized with serious adverse events, including cardiac arrest, and died.

What FDA found

  1. The investigator failed to ensure the investigation was conducted according to the investigational plan; a subject received about 100 times the protocol-required dose after dilution procedures were not followed.

    21 CFR 312.60

What FDA wants

Within 15 business days of receipt, notify FDA in writing of actions taken to prevent similar violations and provide sufficient details on how the investigator will oversee study procedures. Failure to address the matter adequately may lead to regulatory action.

Who should pay attention

  • clinical investigators running drug trials
  • sponsors and IRBs overseeing investigational drug studies
  • oncology research pharmacies and compounding staff

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Jose M. Carpio, M.D.

    FDA warned clinical investigator Dr. Jose Carpio of Miami Lakes, FL, that trial subjects received less than the protocol-required dose of study drug.

    Medium
  2. Bertrand P. Cole, D.O.

    FDA warns Dr. Bertrand P. Cole that he gave four trial subjects too much drug by not following the study plan.

    High risk
  3. Purushothaman Damodara Kumaran, M.D. / Senthil Specialty Hospital

    FDA warned Senthil Specialty Hospital and Dr. Purushothaman Damodara Kumaran about missed safety monitoring in a bioequivalence study of an investigational drug.

    High risk